Humoral Response of Different Types of SARS-CoV-2 Vaccines in Patients with Autoimmune Rheumatic Diseases: Experiences from a Serbian Cohort.

Autor:	Stojanovich L; Special Hospital 'Dr Zutic', Belgrade University, Belgrade, Serbia., Stanisavljevic N; Department of Hematology, University Hospital Medical Center Bezanijska Kosa, Belgrade, Serbia, Faculty of Medicine, Belgrade University, Belgrade, Serbia., Djokovic A; Department of Cardiology, University Hospital Medical Center Bezanijska Kosa, Belgrade, Serbia, Faculty of Medicine, Belgrade University, Belgrade, Serbia., Milanovic M; Infectology Clinic, Military Medical Academy, Belgrade, Serbia., Saponjski J; Faculty of Medicine, Belgrade University, Belgrade, Serbia, Clinic of Cardiology, University Clinical Center of Serbia, Belgrade, Serbia., Shoenfeld Y; Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Jazyk:	angličtina
Zdroj:	The Israel Medical Association journal : IMAJ [Isr Med Assoc J] 2023 Sep; Vol. 25 (9), pp. 590-594.
Abstrakt:	Background: Data are scarce on the immunogenicity of coronavirus disease 2019 vaccines in patients with autoimmune rheumatic diseases (ARD). Objectives: To measure the immunoglobulin G (IgG) response after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunization and to evaluate clinical characteristics associated with seropositivity. Methods: Samples were collected after the second and third doses of the three different types of vaccines in ARD patients. Seroconversion rates and IgG antibody S1/S2 titers were measured. Results: The type of ARD diagnosis and previous treatment had no significant impact on the serum IgG antibody levels measured after the second (P = 0.489 and P = 0.330, respectively) and boost dose (P = 0.441 and P = 0.446, respectively). What made a significant difference regarding serum IgG antibody levels after the second dose was the type of SARS-CoV-2 vaccine. The difference was highly statistically significant for all vaccine types (P = 0.001 with the highest odds ratio for the mRNA vaccine). After the boost with the mRNA vaccine, all patients achieved a high level of serum IgG antibody levels (t = 10.31, P = 0.001). No ARD patients experienced serious post-vaccinal reactions. Eight patients developed COVID-19 before the boost dose. Conclusions: In ARDs patients, the highest level of serum IgG antibody against S1/S2 proteins was achieved with the mRNA vaccine, irrespective of the therapy applied or the type of the disease. We recommend a booster dose with mRNA vaccine in all ARDs for the highest SARS-CoV-2 protection without serious post-vaccinal reactions observed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu